Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease

✍ Scribed by Laurie A. Milner; Michael W. Becker; Steven H. Bernstein; Lauren Bruckner; Jonathan W. Friedberg; George A. Holland; J.J. Ifthikharuddin; Jane L. Liesveld; Edward J. Mathes; Heather L. Menchel; Craig A. Mullen; Talia Sasson; Gordon L. Phillips II

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 681 KB
• Volume: 86
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.22075

✦ Synopsis

Staging System and chromosomal abnormalities determined by standard metaphase karyotype and/or fluorescence in situ hybridization (FISH). Treatment-induced adverse events were graded according to the National Cancer Institute common terminology criteria for adverse events (CTCAE) version 4.0. For response assessment we utilized the International Uniform Response Criteria for Mutiple Myeloma .

The main endpoint of the study was to determine the overall response rate for high-dose cyclophosphamide in bortezomib-refractory MM patients. Secondary endpoints were to determine median overall survival, frequency and severity of adverse events. Progression free survival and duration of response was not estimated since this endpoint was distorted by the high proportion of patients undergoing transplantation immediately after a response was obtained. We reported proportions with their respective 95% confidence intervals. Continuous numerical variables were described using their median and range. Overall survival was described utilizing the method of Kaplan-Meier. Statistical analysis was performed the software SPSS (version 16).